Graft-versus-host disease (GVHD) is a common – and potentially fatal – complication following bone marrow and solid organ transplants. This life threatening condition can also occur after a patient receives a blood transfusion or other forms of transplanted tissue from a genetically different person.
Cannabidiol (“CBD”) products are suddenly everywhere. But as much as opportunity and possibility have opened in the hemp-derived CBD industry, so too have legal pitfalls and snares that can confuse just about anyone breaking into this new market. When it comes to navigating the trails that are still being blazed, many are left wondering, “Is it legal or not?”
At a time when the popularity of CBD and hemp products meets legalization, the importance of this question cannot be overstated. Unfortunately, the answer is not an easy one. Individuals and companies alike are stepping forward with innovative ideas and using these products in health supplements, topical ointments, and even food and beverages. What they often find at all stages of production (manufacturing, distribution, and marketing), is that the law can be ambiguous and varied, especially when divided by state lines and the unavoidable intersections with federal law.
Our attorneys have been at the forefront of the struggle to effectively interpret and understand these challenging legal circumstances. On August 16th at 11 am PST, Harris Bricken attorneys Daniel Shortt and Alison Malsbury will present a webinar entitled “CBD Legal or Not: How State and Federal Laws Govern the Manufacture, Marketing & Distribution of CBD Products.”
Whether you are an individual or part of a company, working with U.S. or foreign grown products, an attorney or a government official, this webinar will equip you with the knowledge you need to successfully untangle the legal knots that may be preventing you or your clients from realizing the full potential of this industry. Our attorneys will discuss current state and federal laws, marketing do’s and don’ts, trademark protections, and FDA regulations. They will also address audience questions throughout the presentation.
To register, please go here. Move fast, as early bird pricing ends on August 3rd!
In the meantime, for more on CBD law, check out the following:
- Federal Trademarks for Cannabis CBD? The USPTO Says “No.”
- Hemp-Derived CBD Not Allowed in Food (or Pretty Much Anything Else) in California
- Industrial Hemp: Oregon and Interstate Sales
- Labeling CBD Products: The Unique Case of Indiana
- The End of Industrial Hemp Prohibition: Almost There!
- Top 5 Things Your CBD Business Needs to Consider
- Industrial Hemp: Don’t Forget About State Law!
- DEA Confirms It Cannot Regulate All Parts of the Cannabis Plant
- Cannabis Taxation: Does IRC Section 280E Apply to Industrial Hemp?
- Federal Court Denies Review of DEA’s Marijuana Extract Rule
- Legal Hemp: Coming Soon Nationwide?
- Is CBD Legal? Hemp Industry Case Ruling Due Soon
- Target Sold CBD Online: Was it Legal?
At the end of June, the U.S. Senate passed its version of the 2018 Farm Bill, which included the full text of McConnell’s Hemp Farming Act of 2018. If the Senate version is enacted, hemp and derivatives, extracts, and cannabinoids derived from hemp would be treated as agricultural commodities and removed from the purview of the Controlled Substances Act and the Drug Enforcement Administration. Though this is certainly exciting news, it’s not quite time to pop the CBD-infused champagne just yet.
Both the Senate and the House have passed their own versions of the Farm Bill. The Senate included the full text of McConnell’s Hemp Farming Act, but the House version was silent on hemp. The Farm Bill covers a vast range of agricultural issues including subsidies and crop insurance. Now the House and Senate must harmonize their versions of the Bill, including the provisions that relate to industrial hemp.
The House and Senate passed motions to proceed to conference for their respective the Farm Bills. Both chambers will need to agree on which portions of each bill will be included in a conference agreement. U.S. Hemp Roundtable compiled a list of conferees for the House and Senate. The House is represented by 47 conferees and the Senate is represented by 9 conferees.
The 9 Senate conferees show that the both Republicans and Democrats will be represented. The Senate Republicans will include Pat Roberts (Kan.), John Hoeven (N.D.), Joni Ernst (Iowa), John Boozman (Ark.), and Senate Majority Leader Mitch McConnell (Ky.). Senate Democrats Debbie Stabenow (Mich.), Patrick Leahy (Vt.), Sherrod Brown (Ohio). and Heidi Heitkamp (N.D.) will also negotiate on behalf of the Senate.
McConnell’s involvement is important for industrial hemp. McConnell was instrumental in passing the 2014 Farm Bill’s industrial hemp provision and continues to advocate for legalizing hemp. He even recently toured a hemp cultivation facility in Kentucky, as reported by the Lexington Herald Leader. He also happens to be the Senate Majority Leader making him one of the most powerful politicians in the country.
Here’s what McConnell had to say about the 2018 Farm Bill and his decision to sponsor the Hemp Farming Act:
I have proudly served on the Agriculture Committee since my first day in the Senate and know exactly how important this legislation is to agricultural communities across Kentucky, so as Majority Leader, I put myself on the Conference, and we’re ready to get to work to ensure the future of American agriculture. I will advocate for Kentucky’s multi-billion-dollar agriculture industry that supports thousands of good jobs and families in nearly every corner of the Commonwealth. Additionally, I will strongly advocate to legalize industrial hemp. I’m optimistic that my Hemp Farming Act, which I secured in the Senate bill, will be included in the final bill sent to the President for his signature. I am also glad to have the support of Congressman Comer on the Conference for legalizing industrial hemp.
If the House and Senate reach a resolution, they will issue a Conference Report that will be sent back to the House and Senate for final passage. If the passed in both chambers, the Bill would head to the Donald Trump’s desk for signature. For industrial hemp farmers, the sooner this happens, the better.
The 2014 Farm Bill is set to expire on September 30 or at the end of the applicable crop year. Hemp farmers operating under the 2014 Farm Bill will certainly be watching carefully to see whether the 2018 Farm Bill is signed prior to that date. If the 2014 Farm Bill expires, so too will the legal basis for cultivating industrial hemp under federal law. It’s possible that the 2014 Farm Bill will be extended in the event that the 2018 Farm Bill fails to pass. McConnell is hoping that the conference can reach agreement by Labor Day.Read More
Jul 31, 2018 | News |
Marijuana has had a turbulent history in the United States. Starting in the mid-1990s, however, there was a push to introduce the medical benefits of cannabis to the American people once again— ”once again,” because before the 20th century, marijuana was almost entirely legal.
Is your analytical testing budget larger than wanted? We lowered our pricing and are offering an incredible deal. Analytical Tests Only $30 Potency: Flower and Concentrates Residual Solvents: all Matrices Terpenes: Flower and Concentrates We are not newbies to the analytical laboratory business…. The people making up Altitude Consulting have over a 100 combined years of analytical chemistry experience. We have aided in setting up over 150 laboratories around the world. Our experience in the laboratory was gained as analysts, lab managers, service engineers, and business owners. We began developing the first potency methods over 10 years ago which...Read More
Altitude Consulting is not only a hemp testing laboratory, but an organization trusted to consult within the industry. Home growers and commercial farms around the world recognize that EPA based methodologies assure the most accurate and consistent data. Give us a call or bring us a hemp potency, residual solvent or terpene profile sample and see the difference.